Identifications of Inflammatory and Fibrotic Biomarkers in Non-alcoholic fatty liver disease (NAFLD) Patients

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Healthy volunteers to provide blood sample to compare with patients with Primary Biliary Cirrhosis (PBC) and NAFLD"
Age:
50-65
Gender:
Female
Healthy Volunteers:
Yes
Keywords:
NASH, NAFLD, fatty liver disease, liver
Type:
Observational Study
Target:
50 Participants
Investigator:
Description
Primary biliary cirrhosis (PBC) is a disease that occurs due to injury to the bile ducts in your liver. This damages liver tissue and often leads to scarring of the liver called cirrhosis. It is considered an autoimmune disease, a disease in which your body’s own cells turn against itself. It is estimated that 5-40 people out of every 100,000 people in the US and Europe suffer from PBC. Current research suggests the disease is caused by a combination of environmental exposures and genes.

Non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH) are common, often “silent” liver diseases. NASH resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NAFLD/NASH is fat in the liver, along with inflammation and fibrosis. NASH can be severe and can lead to cirrhosis and hepatocellular carcinoma (a type of liver cancer). 10 to 20 percent of Americans have NAFLD with NASH affecting 2 to 5 percent of Americans.

This study is being done to find out more about the difference in naturally occurring proteins in patients with PBC and NAFLD. Current research suggests that the body’s immune response, its natural response to fight infection and disease, may be involved in causing damage to the bile duct tissue. This research hopes to identify proteins that are related to PBC and NAFLD and if new treatments can be developed which affect these proteins.
This study requires
Questionnaire
Fasting blood sample (Blood drawn after 10- hour overnight fast)
Who can participate?
Healthy women 50 to 65 years old that have no history of liver disease and that are not currently taking immunosuppressive medication.

Please contact for more details
Compensation
$20 prepaid Target card
Resources
Schedule
Study duration and period
One visit, approximately 30 minutes: Fasting (10 hours overnight) blood draw Questionnaire
Recruitment period
From Feb. 2, 2015
Location
UC Davis Gastroenterology/Hepatology Clinical Trials Unit
2000 Stockton Boulevard
Ticon I Building, Suite 100
Sacramento, CA 95817
Contact
Chung Heng Liu

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview